Hadasit Bio-Holdings

Press Releases

D Pharm Ltd. - Update Regarding Focus of Company Activity and Infrastructure Adaptation

Oct. 27, 2015

HBL – Hadasit Bio-Holdings Ltd.

(the “Company”)

October 27, 2015

 

To                                                       To

Israel Securities Authority                 Tel Aviv Stock Exchange Ltd.          

www.isa.gov.il                                    www.tase.co.il

 

 

Re: Update Regarding Focus of Company Activity and Infrastructure Adaptation 

 

The Company is announcing  that D Pharm Ltd., a company traded on the Tel Aviv Stock Exchange in which the Company holds a 5.57% stake (hereinafter: “D Pharm”), filed an immediate report today stating that on October 26, 2015 the D Pharm board of directors resolved that D Pharm would focus its managerial and financial resources on the following activities: (a) development of D Pharm's flagship product, the THR-18, including the performance of Phase IIa clinical trials on patients who suffered an ischemic stroke and are being treated with tPA in conjunction with THR-18; (b) continued cooperation with Jiahgsu Nhwa Pharmaceutical Co. Ltd. in the development of the DP-VPA product intended for treatment of epilepsy and manic depression; and (c) identification of a strategic partner for the further development of D Pharm's products.

 

Further to the above, the D Pharm board of directors instructed D Pharm management to immediately act to adapt D Pharm's infrastructure (manpower, offices and associated expenses) to the new scope of activity.

 

D Pharm will provide future updates with regard to actions taken.

 

For more information concerning D Pharm's report on this matter, see D Pharm's immediate report dated October 27, 2015 (reference number 2015-01-142683).        

 

                                                                                   

Sincerely

 

HBL – Hadasit Bio-Holdings Ltd.

      By: Ms. Tamar Kfir, CEO

 
 

Press Releases Archive